Amro Albanna (00:20): Jeff as we have done in the past. Let's just wait to see who's joining. I don't know if you can see it on your side as well, but so far we're just seeing people join and I'm waiting for those who ca

Amro Albanna (00:20):

Jeff as we have done in the past. Let's just wait to see who's joining.

I don't know if you can see it on your side as well, but so far we're just seeing people join and I'm waiting for those who can hear us.

We're just waiting a little bit for everybody to get a chance to join the Zoom call. Okay. Maybe we can get started. I think everybody

knows Jeff Ramson. Jeff, maybe just one-liner, quick intro here. Obviously I'm the co-founder and CEO of Aditxt. And Jeff, just maybe

a quick one-liner as far as far as you.

Jeff Ramson (01:11):

Sure. I'm the founder and CEO of PCG advisory, full service investor

Amro Albanna (01:17):

Great. And Jeff has been working with us for actually pretty much from

the very beginning. So he understands the company and understands the market, the landscape, and I will encourage and I see our team members

joining today. I do encourage you to please go ahead and ask any questions that would be very helpful maybe to others who are thinking

of the same question. Today we are going to focus on what we must accomplish as a company and what we're looking to accomplish as a company

the remainder of this quarter and in Q3. And it is important with all the activities that are going on in the company, whether it's product

development, whether it's operations, whether it's finance and other activities for all of us collectively inclusive of our stakeholders

to understand what the plan is and how that plan is in alignment with our objectives. So that's what we'll focus on and Jeff and I spoke

before to really frame the conversation around this. So the best way to do it is to really begin from the end by end of Q3, what is it

that we want to see Aditxt and what position we want to see Aditxt at. And to summarize it, and Jeff please jump in in terms of framing

the same thing we just discussed.

Our goal is to position Aditxt with our current programs and any future

program that we will have in a way that is focused on growth. Right now, there is no secret that, and frankly not just us, but other microcap

companies who may be dealing or at the same stage as we are right now, you got to survive while growing the business. You got to survive

while you move forward with the business. And there is obviously no secret that there are interruptions that take place when you're trying

to do both at the same time. And that is perfectly fine. That is frankly the rite of passage when you are trying to build an early stage

business to get it to the point where it is positioned for growth. And what does growth mean? Meaning you have the resources needed to

advance every program forward over the next year, two or three years. That's really our definition of growth. So our plan and all the

activities that we are working on is to get Aditxt by end of Q3 to the point where we can become more growth oriented rather than just

more a speculative or as a speculative company. Jeff, so before we move on, maybe you can touch on that a little bit and maybe you can

use your own words to describe what I just shared.

Jeff Ramson (04:08):

Yeah, well yeah, I think that echo your thoughts about one, what it's

like to be a microcap public company in this environment. And we've talked about this a bit over the last few months. I mean, it is really,

really challenging and I think the idea of looking at what can be done incrementally over the defined period that we're talking about

is very important. I think it's important to keep focusing on things that you can control and things that you can accomplish in these

next two, well, the remainder of this quarter and the following. I think that's a great place to be focusing right now.

Amro Albanna (04:45):

Great. So I think just given the fact that we still have some acquisitions,

I'm going to put those aside because those are still uncertain until they are, and we can talk about what growth looks like for Adimune

and what growth looks like for Pearsanta because those are our subsidiaries, those are our current programs. So Adimune must continue

without interruption, with focus towards clinical trials, human trials. So we've been working on the platform and the program for years

and our focus is to move Adimune forward towards human trials. And of course if we're granted approvals, then we begin to focus on safety

and eventually efficacy. So that would be the focus for Adimune over the next, again, year two and three years. And that we need to at

least put Adimune in a position that by end of September there is a clear path as far as resources where they can begin moving forward.

And frankly with the bigness of Adimune and what it is that they're

working on, truly resources is the gating factor for Adimune and we continue to address that where obviously we've never been dead in

the water. We continue to find ways to keep the program moving forward, whether it's through partnerships or through working with our

vendors closely. So that's kind of the definition of Adimune. Pearsanta, by end of Q3, we also want to do the same thing. We want to make

sure that Pearsanta has the tools and resources that they can proceed forward without. There'll always be interruptions, but at least

without uncertainty when it comes to resources, whether it's over a midterm, six months, 12 months, and of course two years and three

years. That's our goal. And the path for Pearsanta is to focus on validation, the validation of the first two assays, which is endometriosis

and prostate cancer.

So these are the two programs. Now when it comes to the acquisitions,

those are still uncertain and we'll see where we end up with each, which is also dependent on resources that we can secure. So that's

on the program side. And some of you who were on the call last week, we now got to go back to the financial side of the equation. So part

of us being positioned for growth, obviously we have to have the financial resources to allow us to do two things. One, to address remaining

obligations, past obligations. That is always a must. And without getting into all the details, which may or may not be relevant, some

of our cap table and some of the securities and the structure of those securities would have to be addressed. Our balance sheet and some

of the outstanding payables and debts would have to be addressed, maybe reduced, maybe fully paid, but that would have to be addressed.

But we also have to have the resources to allow us to move forward.

So by end of Q3, we got to make sure that both companies and other ones as well potentially are ready or ready to continue on the path

that I just shared. But we also have to have the financial resources and addressing any past obligations and forward needs that we need

now whether it's six months or 12 months, but certainly we need more than the short term availability that we've had to navigate through

in the last few years. So Jeff, what are your thoughts?

Jeff Ramson (08:43):

Yeah, I think that the capital strategy is critical. I know that's

something you're working very hard on. I guess I had one question if you don't mind, regarding Pearsanta. I know that there was an announcement

about potential IPO this year. Is that something you want to, can you address that right now or, I know it's still uncertain, but is that

something you can talk a bit about?

Amro Albanna (09:09):

Yeah, I'll talk about it Jeff. So obviously today, let's just say even

we have the tools to launch or spin off Pearsanta, which is part of our business model, but today no one would recommend doing such thing.

It's simply not a market. It is not right for Aditxt stakeholders even or Pearsanta stakeholders to think about that right now. I mean

it's just not the market for microcap, actually not the market for IPOs period, let alone. So our orientation remains to be the same.

I don't know if it's this year, I don't know if it's early next year. I think that will have to be determined based on conditions on the

ground and how far Pearsanta is. And what I would say is the farther into commercialization Pearsanta is the better that spinoff will

Period. And working with the team at Pearsanta and Chris, we got to

make sure we do everything we can and the team is doing everything they can and we're doing everything we can collectively to make sure

that you still got to move towards commercialization. Because whether it's IPO or not, ultimately Pearsanta has to be an exciting viable

business, which absolutely, I mean when you're talking about endometriosis and prostate cancer and followed by ovarian and other types

of cancer, obviously the core of the business is there, but now we have to get 'em into commercialization because the value of the business

and the maturity of the business will increase when we get there. So the quick answer, Jeff, is that plan remains the same. Timing is

dependent on conditions all around.

Jeff Ramson (10:53):

Understood. And yeah, if I could just put my 2 cents in, yeah, I would

agree with that too. As I said, we deal with a number of companies and all the investment banks, it's really, really difficult right now

getting IPOs done, deals that are getting priced are much smaller, they're not getting premium valuations. It is a difficult time. So

I do agree that it makes sense to wait for one conditions to change and then as Pearsanta's even further along, it will certainly attract

Amro Albanna (11:24):

Someone told me, and I certainly don't know this for a fact, but someone

told me that they saw an IPO for $2 to $3 million from my point of view, why? I mean, how can you go out as a public company with all

the expenses and overhead with $2 to $3 million when you have to go raise money basically next weekend.

Jeff Ramson (11:46):

Amro Albanna (11:47):

That's certainly not a position we want to put Pearsanta in.

Jeff Ramson (11:51):

Yeah, understood. Agreed.

Amro Albanna (11:56):

I see at least 18 people and just in case you came in and joined in

late or 21, please go ahead and ask any questions. Jeff and I are here and we want to make sure that we continue this. In fact, every

time we talk about it right before Jeff says, are we on? And I say, we got to keep this thing on. We got to make sure that we're communicating